Published in Lancet Oncol on August 13, 2012
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52
Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol (2015) 1.50
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol (2014) 1.09
Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep (2013) 0.94
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol (2015) 0.92
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol (2015) 0.87
Targeting brain metastases in patients with melanoma. Biomed Res Int (2013) 0.87
Tumor localized secretion of soluble PD1 enhances oncolytic virotherapy. Cancer Res (2017) 0.85
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol (2013) 0.85
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunol Res (2015) 0.85
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med (2016) 0.84
The delicate balance of melanoma immunotherapy. Clin Transl Immunology (2013) 0.83
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol (2015) 0.82
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Oncoimmunology (2015) 0.82
Systemic Immunotherapy for the Treatment of Brain Metastases. Front Oncol (2016) 0.82
Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res (2016) 0.81
Latest approved therapies for metastatic melanoma: what comes next? J Skin Cancer (2013) 0.80
Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr Oncol Rep (2013) 0.80
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. J Transl Med (2013) 0.79
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. J Transl Med (2016) 0.78
Clinical trials in melanoma patients with brain metastases. Pigment Cell Melanoma Res (2015) 0.78
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol (2015) 0.78
Targeted Therapies for Melanoma Brain Metastases. Curr Treat Options Neurol (2017) 0.77
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. Vaccines (Basel) (2015) 0.77
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial. Transl Oncol (2016) 0.77
Emerging options for the treatment of melanoma - focus on ipilimumab. Immunotargets Ther (2014) 0.77
Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model. Mol Pharm (2013) 0.76
Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Ther Adv Med Oncol (2015) 0.76
Cancer testis antigen and immunotherapy. Immunotargets Ther (2013) 0.76
Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep (2016) 0.75
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother (2016) 0.75
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol (2017) 0.75
Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature. Case Rep Oncol (2013) 0.75
The role of checkpoints in the treatment of GBM. J Neurooncol (2015) 0.75
Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches. Front Oncol (2017) 0.75
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. Medicine (Baltimore) (2016) 0.75
Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75
Ipilimumab with fotemustine in metastatic melanoma. Lancet Oncol (2012) 0.75
Embracing rejection: Immunologic trends in brain metastasis. Oncoimmunology (2016) 0.75
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. Oncoimmunology (2015) 0.75
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. Oncoimmunology (2017) 0.75
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer (2007) 3.80
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005) 3.64
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2013) 3.28
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 3.10
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev (2006) 2.87
Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res (2007) 2.80
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res (2006) 2.77
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol (2011) 2.62
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res (2006) 2.61
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol (2009) 2.48
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 2.28
Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol (2002) 2.27
A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2004) 2.16
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg (2015) 2.04
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst (2004) 2.02
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology (2005) 2.00
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics (2005) 1.99
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother (2011) 1.94
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol (2005) 1.88
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.87
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res (2009) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol (2006) 1.75
Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. Crit Rev Oncol Hematol (2007) 1.75
Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood (2010) 1.74
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol (2010) 1.73
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
Main roads to melanoma. J Transl Med (2009) 1.67
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67